Dupixent Lawsuit

Dupixent has been linked to a rare type of skin cancer called Cutaneous T-Cell Lymphoma (CTCL) in recent studies.

What You Can Do & How We Can Help

The Schmidt Firm, PLLC is currently accepting Dupixent injury cases in all 50 states. If you or somebody you know was diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

UPDATE: FDA Evaluating Dupixent Cancer Risk

The FDA is currently “evaluating the need for regulatory action” while health officials investigate reports linking Dupixent and Cutaneous T-Cell Lymphoma (CTCL), according to an update: October – December 2024: Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS).

What is the Problem?

Studies have found evidence linking Dupixent and Cutaneous T-Cell Lymphoma (CTCL). For example, one study found that people who used Dupixent were 4-times more likely to develop CTCL. The FDA is currently evaluating the need for regulatory action. In the meantime, patients and doctors may not be aware of the risk of this severe, life-threatening side effect.

Dupixent and Skin Cancer

CTCL is commonly called a skin cancer because it affects the skin, but it is actually a rare type of non-Hodgkin lymphoma, which is a blood cancer. CTCL occurs when the body’s germ-fighting white blood cells called T-cells or T-lymphocytes grow uncontrollably on the skin and form tumors that look like a rash.

Dupixent Lawsuits for T-Cell Lymphoma

Lawyers are investigating Dupixent lawsuits against the drug-manufacturers for failing to warn patients about the risk of CTCL from Dupixent. People who were diagnosed with skin cancer or CTCL after using Dupixent may be eligible to seek justice and compensation by filing a lawsuit or joining a class action.

Study Finds 300% Higher Risk of T-Cell Lymphoma

In April 2024, a study published by Hasan et al. found that people who took Dupixent had a 300% higher risk of developing CTCL compared to people who did not take Dupixent.

Another Study Links Dupixent and T-Cell Lymphoma

In August 2024, researchers led by Dr. Jenna Mandel discovered an increased risk of cutanetous T-cell lymphoma after Dupixent was used for atopic dermatitis. According to the study:

“To date, there have been a total of 39 documented CTCL cases following dupilumab use for treatment of AD worldwide, many of which progressed rapidly to advanced-stage disease.”

Dupixent Cancer Risk Highest for People Over 60

in January 2024, a study published by Dr. Jenna Mandel confirmed a link between Dupixent and CTCL. The risk was highest for people over 60 years old, especially during their first year of treatment. Alarmingly, many cases progressed rapidly.

Source: Mandel, J. Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis. Dermatol Ther. 2024 Jan.

CTCL Can Be Mistaken for Eczema

CTCL is rare, but it can mimic the symptoms of eczema, which is why it may go undiagnosed for years. Studies suggest a possible risk that Dupixent may “unmask” or worsen a hidden pre-existing case of CTCL that was mistaken for eczema. The researchers urge doctors to re-evaluate patients who do not improve with Dupixent treatment, especially if they have unusual skin reactions.

What is Dupixent?

Dupixent® is a medication that was approved for moderate-to-severe atopic dermatitis (AD) in 2017. It is commonly used to treat eczema. Dupixent was jointly developed by two drug companies, Sanofi and Regeneron Pharmaceuticals.

What is CTCL?

Cutaneous T-Cell Lymphoma (CTCL) is often referred to as a type of skin cancer, but it is actually a rare type of non-Hodgkin lymphoma that affects the skin. The lymphoma generally causes a skin rash, and in the most common type of CTCL (mycosis fungoides) the rash looks just like eczema or psoriasis. This rash may persist for years or even decades before it is diagnosed.

Symptoms of Cutaneous T-Cell Lymphoma (CTCL)

According to the Mayo Clinic, symptoms of Cutaneous T-Cell Lymphoma (CTCL) may include:

• Skin lesions
• Raised bumps or plaques
• Skin rash that is scaly or itchy
• Red, scaly patches on the skin
• Thickened, leathery skin (especially on palms of the hands and soles of the feet)
• Enlarged lymph nodes
• Hair loss
• Fatigue or unexplained weight-loss

How Can a Lawsuit Help?

Every case is unique, and there is never a guarantee of a settlement or jury verdict. Even so, lawsuits involving dangerous side effects of prescription medications will typically seek financial compensation for:

• Pain and suffering
• Past and future medical expenses
• Lost wages
• Permanent injuries, disability, or disfigurement
• Decreased quality of life
• Wrongful death
• And more

Do I Have a Dupixent Lawsuit?

The Schmidt Firm, PLLC is currently accepting Dupixent injury cases in all 50 states. If you or somebody you know was diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.